Text Size
8 studies found for:    immune thrombocytopenia OR immune thrombocytopenic purpura OR idiopathic thrombocytopenic purpura | Open Studies | NIH, U.S. Fed

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia
Conditions: Anemia, Aplastic;   Anemia, Hypoplastic;   Thrombocytopenia
Interventions: Drug: Eltrombopag (Promacta);   Drug: Eltrombopag
2 Recruiting Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Conditions: Aplastic Anemia;   Neutropenia;   Pancytopenia;   Anemia;   Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Horse Anti-Thymocyte Globulin (ATG);   Drug: Cyclosporine A (CSA)
3 Recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath(Registered Trademark))
4 Unknown † Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
5 Recruiting Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: rituximab;   Drug: PGG beta-glucan;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Genetic: DNA analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Genetic: mutation analysis
6 Recruiting Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Thrombocytopenia
Intervention: Biological: romiplostim
7 Recruiting Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia
Interventions: Biological: human myeloid progenitor cells;   Drug: G-CSF
8 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
To Top

† Indicates status has not been verified in more than two years